These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prevalence of hepatitis B in children in a high risk New Zealand community, and control using recombinant DNA vaccine.
    Author: Milne A, Heydon JL, Hindle RC, Pearce NE.
    Journal: N Z Med J; 1989 Apr 26; 102(866):182-4. PubMed ID: 2523525.
    Abstract:
    Two hundred and sixty-six children aged 3-10 years were tested for hepatitis B virus (HBV) serologic markers. Thirty-eight were positive, including seven who were positive for hepatitis B surface antigen (HBsAg). Two hundred and fifteen healthy children were randomised to receive either 3 x 5 micrograms doses or 3 x 10 micrograms doses of Smith Kline Biologicals Engerix B recombinant DNA (rDNA) hepatitis B vaccine into the deltoid muscle at 0, 1 and 6 months. They were tested for seroconversion and levels of antibody to hepatitis B surface antigen (anti-HBs) one month after dose 3. Ninety-nine percent of children in each group seroconverted for anti-HBs. Geometric mean titres (GMT) or anti-HBs in IU/L were higher with 10 micrograms doses. Nevertheless, 3 x 5 micrograms is the appropriate regimen for protecting children in this age group, as long as cost of vaccine remains a major factor in immunisation programmes.
    [Abstract] [Full Text] [Related] [New Search]